RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Zeitschrift fur Rheumatologie · 2026
   Article
2. [New results from the RABBIT register on the cancer risk of patients with rheumatoid arthritis treated with Janus kinase inhibitors].Zeitschrift fur Rheumatologie · 2026
   Article
3. Janus kinase inhibitors effectively improve pain across different disease activity states in rheumatoid arthritis.Internal and emergency medicine · 2023
   Article
4. JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.The Journal of allergy and clinical immunology · 2021
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as